Novartis's Multiple Sclerosis Trial Results Match Best Hopes
Dow Jones
Yesterday
1414 GMT - Novartis's trial results for a multiple sclerosis drug are in line with a blue-sky scenario, UBS analysts say in a research note. The Swiss drugmaker's results from two late-stage studies point to a greater reduction in annualized relapse rates with its Rhapsido compared to Sanofi's Aubagio, with no liver safety issues, the analysts say. These results suggest Novartis's drug might be at least a best-in-class oral medicine for the disease, according to UBS. UBS estimates that there's a 50% probability the drug's sales for relapsing multiple sclerosis reach $4.5 billion. Novartis shares jump 6.2%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.